Noble Financial Reaffirms Their Buy Rating on TherapeuticsMD (TXMD)

By Carrie Williams

In a report issued on July 15, Ahu Demir from Noble Financial maintained a Buy rating on TherapeuticsMD (TXMDResearch Report), with a price target of $10.00. The company’s shares closed last Tuesday at $2.24.

According to TipRanks.com, Demir is a 5-star analyst with an average return of 48.3% and a 64.6% success rate. Demir covers the Healthcare sector, focusing on stocks such as Onconova Therapeutics, Dyadic International, and Cocrystal Pharma.

TherapeuticsMD has an analyst consensus of Moderate Buy, with a price target consensus of $7.50.

See today’s analyst top recommended stocks >>

The company has a one-year high of $4.32 and a one-year low of $0.85. Currently, TherapeuticsMD has an average volume of 5.51M.

Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TXMD in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

TherapeuticsMD, Inc. is a pharmaceutical company, which focuses on developing and commercializing products for women. Its technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. The firm also manufactures and distributes branded and generic prescription prenatal vitamins, as well as over-the-counter vitamins under the BIJUVA, IMVEXXY, vitaMedMD and BocaGreenMD brands. The company was founded by Robert G. Finizio and Brian A. Bernick in 1907 and is headquartered in Boca Raton, FL.